SOM 230 / Pasireotide
R6-937
Phase 1 small_molecule completed
Quick answer
SOM 230 / Pasireotide for Atypical Ductal Breast Hyperplasia is a Phase 1 program (small_molecule) at United Therapeutics Europe Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- United Therapeutics Europe Ltd
- Indication
- Atypical Ductal Breast Hyperplasia
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed